Get Premium

Get Premium

Dominate Financial Markets with Stock Target Advisor Premium Features

Analyst Ratings
Analyst Ratings

Daily targets and ratings from professional analysts
- LATEST ANALYST RATINGS
- Latest Analyst Ratings
- Top Analysts Screener
- Analyst Directory
- My Analysts
- LATEST RATINGS BY COUNTRY
- Canada
- USA
- UK
- India
- France
- Germany
Best Stocks
Best Stocks

Quickly zoom in on the stocks with highest and lowest potential based on analyst recommendations and Stock Target Advisor's own analysis
- Automatic Selection
- Top Stocks
- Worst Stocks
- Best Penny Stocks
- Best Performing Stocks
- Worst Performing Stocks
- Best Stocks Filters
- All Countries
- Canada
- USA
- UK
- India
- France
- Germany
Smart Screens
Smart Screens

Search stocks using 100s of variables and make your own screens
- Search
- Stock Screener
- Advanced Stock Search
- Industries
- Prebuilt Screens
- Popular Screens
- Cryptocurrency Stocks
- Canadian SPACs
- US SPACs
- High Dividend Stocks
- Low Cost Global Equity ETFs
- Reputable Companies
Watchlists & Portfolios
Watchlists & Portfolios

Track and analyze your holdings and favorite stocks
- My Watchlists
- My Portfolios
News & Calendars
News & Calendars

Stay on top of what’s happening in all markets
Insights
Insights

Latest research and insights from our analysts and users
Crowd Ratings
Crowd Ratings

Targets and analysis from users like you
Pricing
About Us

Aileron Therapeutics Inc Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

Submit your target Discuss Add to watchlist

Take a Tour

N/A

Average Analyst
Rating

Bearish

Stock Target Advisor
Analysis

Strong Buy

Average User
Rating

Last Closing Price

USD 1.49

Change

0.00 (0.00)%

Market Cap

USD 6.77M

Volume

2.10K

Avg User Target

USD 2.00 (+34.23%)

ALRN

Aileron Therapeutics Inc (USD)

COMMON STOCK | NSD

USD 1.49

0.00 0

Take a Tour

Target Discuss Watchlist

ALRN Annual Financials (USD)

ALRN Quarterly Financials (USD)

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What not to like

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Symbol: ALRN:NSD

What is your target rating?*

Sell

Hold

Buy

What is your target price?*

USD

What is your Time Horizon for the Target Price ( between 0 - 11 months) ?*

- +

Share your analysis

1000 characters left

Get our Premium Service free for 7-days!

Link watchlist to your brokerage
Premium Newsletter
Daily Analyst Ratings
Detailed Stock Analysis
Top Picks
Watchlists and Portfolios
Advanced Screens
Detailed Reports
Donwloadable Data

Join over half-million smart investors across the world

Select Market

I agree to Stock Target Adivsor Terms and Conditions

or Sign up with

ALRN Aileron Therapeutics Inc